Clinical Experience With an L-Proline-Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability

Autor: Dorsey, Morna, Dorsey, MJ, Ho, V, Mabudian, M, Soler-Palacín, P, Domínguez-Pinilla, N, Rishi, R, Wong, D, Rojavin, M

Publikováno v: Dorsey, Morna; Dorsey, MJ; Dorsey, MJ; Ho, V; Mabudian, M; Soler-Palacín, P; et al.(2014). Clinical Experience With an L-Proline-Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/3289r0mw

Purpose This retrospective study evaluated the effectiveness and tolerability in clinical practice of an L-proline-stabilized 10 % intravenous immunoglobulin (IVIG; Privigen®) in patients with primary (PID) or secondary immunodeficiency (SID). Metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::6878643eb4bdb60d3e298cddc897daa7
http://www.escholarship.org/uc/item/3289r0mw

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sulfonamide hypersensitivity and successful desensitization in a patient with end stage renal disease awaiting renal transplantation.

Autor: Vital, C.J., Mabudian, M., Kamboj, S., Kumar, P.

Publikováno v: Journal of Allergy & Clinical Immunology; Feb2005 Supplement, Vol. 115 Issue 2, pS184-S184, 1p

ABLATING THE ISCHEMIA-REPERFUSION INJURY IN NON-HEART BEATING DONOR (NHBD) KIDNEYS

Autor: Hernandez, A, Light, J A, Barhyte, D Y, Mabudian, M, Gage, F

Publikováno v: Transplantation; October 1998, Vol. 66 Issue: 8 pS21-S21, 1p